Drug Profile
Research programme: anticancer antibodies - AltruBio
Alternative Names: AbGn-100; AbGn-108; AbGn-109; AbGn-110; AbGn-150; Antibody-100; Antibody-150; Antibody-8Latest Information Update: 06 Jul 2020
Price :
$50
*
At a glance
- Originator AbGenomics Corporation
- Developer AltruBio
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 25 Mar 2016 Preclinical development is ongoing in USA
- 08 Oct 2014 Preclinical development is ongoing in USA